Plasma Messenger RNAs Identified Through Bioinformatics Analysis are Novel, Non-Invasive Prostate Cancer Biomarkers

References

• Xue D, Zhou CX, Shi YB, Lu H, He XZ. MD-miniRNA could be a more accurate biomarker for prostate cancer screening compared with serum prostate-specific antigen level. Tumour Biol. 2015;36(5):3541–3547. doi:10.1007/s13277-014-2990-x25557788
   PubMedGoogle Scholar
• Peyromaure EM, Mao K, Sun Y, et al. A comparative study of prostate cancer detection and management in China and in France. Can J Urol. 2009;16:4472–4477.19222885
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. doi:10.3322/caac.2007320610543
   PubMed Web of Science ®Google Scholar
• Boyle P, Koechlin A, Bota M, et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int. 2016;118(5):731–741. doi:10.1111/bju.2016.118.issue-526779889
   PubMed Web of Science ®Google Scholar
• Stallone G, Cormio L, Netti GS, et al. Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer. Cancer Res. 2014;74(16):4230–4238. doi:10.1158/0008-5472.CAN-14-036924950910
   PubMed Web of Science ®Google Scholar
• Wei ZR, Liang C, Feng D, et al. Low tristetraprolin expression promotes cell proliferation and predicts poor patients outcome in pancreatic cancer. Oncotarget. 2016;7(14):17737–17750. doi:10.18632/oncotarget.739726894969
   PubMedGoogle Scholar
• Lo KW, Lo YM, Leung SF, et al. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clin Chem. 1999;45:1292–1294.10430801
   PubMed Web of Science ®Google Scholar
• Zhou D, Tang W, Liu X, An HX, Zhang Y. Clinical verification of plasma messenger RNA as novel noninvasive biomarker identified through bioinformatics analysis for lung cancer. Oncotarget. 2017;8(27):43978–43989. doi:10.18632/oncotarget.1670128410204
   PubMedGoogle Scholar
• March-Villalba JA, Martínez-Jabaloyas JM, Herrero MJ, Santamaría J, Aliño SF, Dasí F. Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients. Expert Opin Biol Ther. 2012;12(Suppl 1):S69–S77. doi:10.1517/14712598.2012.68571622559196
   PubMedGoogle Scholar
• Petty RD, Nicolson MC, Kerr KM, Collie-Duguid E, Murray GI. Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application. Clin Cancer Res. 2004;10:3237–3248. doi:10.1158/1078-0432.CCR-03-050315161676
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–180. doi:10.1593/neo.0711217356713
   PubMed Web of Science ®Google Scholar
• Angrand P-O, Vennin C, Le Bourhis X, Adriaenssens E. The role of long non-coding RNAs in genome formatting and expression. Front Genet. 2015;6:165. doi:10.3389/fgene.2015.0016525972893
   PubMed Web of Science ®Google Scholar
• De Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695–2698.11980670
   PubMed Web of Science ®Google Scholar
• Ferreira LB, Palumbo A, de Mello KD, et al. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer. 2012;12:507. doi:10.1186/1471-2407-12-50723130941
   PubMed Web of Science ®Google Scholar
• Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009;6:255–261. doi:10.1038/nrurol.2009.4019424173
   PubMed Web of Science ®Google Scholar
• Thoma C. Prostate cancer: the genomics of localized disease. Nat Rev Urol. 2017;14:65. doi:10.1038/nrurol.2017.428094334
   PubMed Web of Science ®Google Scholar
• Merlo GR, Zerega B, Paleari L, Trombino S, Mantero S, Levi G. Multiple functions of Dlx genes. Int J Dev Biol. 2000;44:619–626.11061425
   PubMed Web of Science ®Google Scholar
• Chan DW, Hui WW, Wang JJ, et al. DLX1 acts as a crucial target of FOXM1 topromote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling. Oncogene. 2017;36(10):1404–1416. doi:10.1038/onc.2016.30727593933
   PubMed Web of Science ®Google Scholar
• Adaramoye O, Erguen B, Oyebode O, et al. Antioxidant, antiangiogenic and antiproliferative activities of root methanol extract of Calliandra portoricensis in human prostate cancer cells. J Integr Med. 2015;13(3):185–193.26006031
   PubMedGoogle Scholar
• Abou-Hashem MM, Abo-Elmatty DM, Mesbah NM, Abd El-Mawgoud AM. Induction of sub-G0 arrest and apoptosis by seed extract of Moringa peregrina (Forssk.) Fiori in cervical and prostate cancer cell lines. J Integr Med. 2019;17(6):410–422.31669164
   PubMedGoogle Scholar
• Alinezhad S, Väänänen RM, Mattsson J, et al. Validation of novel biomarkers for prostate cancer progression by the combination of bioinformatics, clinical and functional studies. PLoS One. 2016;11(5):e0155901. doi:10.1371/journal.pone.015590127196083
   PubMed Web of Science ®Google Scholar
• Altintas DM, Allioli N, Decaussin M, et al. Differentially expressed androgen-regulated genes inandrogen-sensitive tissues reveal potential biomarkers of early prostate cancer. PLoS One. 2013;8(6):e66278. doi:10.1371/journal.pone.006627823840433
   PubMed Web of Science ®Google Scholar
• Lacko M, Ophuis MBO, Peters WH, Manni JJ. Genetic polymorphisms of smoking-related carcinogen detoxifying enzymes and head and neck cancer susceptibility. Anticancer Res. 2009;29(2):753±61.
   Web of Science ®Google Scholar
• Lin X, Tascilar M, Lee WH, et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol. 2001;159(5):1815–1826. doi:10.1016/S0002-9440(10)63028-311696442
   PubMed Web of Science ®Google Scholar
• Maldonado L, Brait M, Loyo M, et al. GSTP1 promoter methylation is associated with recurrence in early stage prostatecancer. J Urol. 2014;192(5):1542–1548. doi:10.1016/j.juro.2014.04.08224769028
   PubMed Web of Science ®Google Scholar
• Hauptstock V, Kuriakose S, Schmidt D, et al. Glutathione-S-transferase pi 1(GSTP1) gene silencing in prostatecancer cells is reversed by the histone deacetylase inhibitor depsipeptide. Biochem Biophys Res Commun. 2011;412(4):606–611. doi:10.1016/j.bbrc.2011.08.00721855532
   PubMed Web of Science ®Google Scholar
• Mian OY, Khattab MH, Hedayati M, et al. GSTP1 loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress. Prostate. 2016;76(2):199–206. doi:10.1002/pros.2311126447830
   PubMed Web of Science ®Google Scholar
• Pettigrew CA, Clerkin JS, Cotter TG. DUOX enzyme activity promotes AKT ignaling in prostate cancer cells. Anticancer Res. 2012;32(12):5175–5181.23225414
   PubMed Web of Science ®Google Scholar
• Ito K, Ota A, Ono T, et al. Inhibition of Nox1 inducesapoptosis by attenuating the AKT signaling pathway in oral squamous cellcarcinoma cell lines. Oncol Rep. 2016;36(5):2991–2998. doi:10.3892/or.2016.506827600098
   PubMed Web of Science ®Google Scholar
• Little AC, Sham D, Hristova M, et al. DUOX1 silencing in lung cancer promotes EMT, cancerstem cell characteristics and invasive properties. Oncogenesis. 2016;5(10):e261. doi:10.1038/oncsis.2016.6127694834
   PubMedGoogle Scholar
• Lu CL, Qiu JL, Huang PZ, et al. NADPHoxidase DUOX1 and DUOX2 but not NOX4 are independent predictors in hepatocellularcarcinoma after hepatectomy. Tumour Biol. 2011;32(6):1173–1182. doi:10.1007/s13277-011-0220-321915726
   PubMedGoogle Scholar